LeMaitre Vascular (LMAT)
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
$80.67+0.22%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
QuarterlyIQ Insights · LMAT
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||||||
| Revenues | — | 249.6 | 219.9 | 193.5 | 161.7 | 154.4 | 129.4 | 117.2 | 105.6 | 100.9 | 89.2 | 78.4 | 71.1 | 64.5 | 56.7 | 57.7 |
| Total Revenues | — | — | — | — | — | — | — | — | — | 100.9 | 89.2 | 78.4 | 71.1 | 64.5 | 56.7 | 57.7 |
| Cost of Revenues | 71.1 | 71.1 | 69.0 | 66.4 | 56.8 | 53.0 | 44.7 | 37.4 | 31.6 | — | — | — | — | — | — | — |
| Gross Profit | 191.3 | 178.5 | 150.9 | 127.0 | 104.9 | 101.4 | 84.6 | 79.9 | 73.9 | 70.7 | 62.9 | 54.2 | 48.4 | 45.1 | 40.9 | 40.2 |
| Operating Expenses & Income | ||||||||||||||||
| R&D Expenses | 15.4 | 14.1 | 15.7 | 17.0 | 13.3 | 11.8 | 10.1 | 9.3 | 8.2 | 6.6 | 6.1 | 5.5 | 4.7 | 5.2 | 5.1 | 4.4 |
| Operating Income | 77.3 | 67.9 | 52.3 | 36.7 | 26.8 | 36.4 | 28.8 | 21.2 | 28.2 | 21.1 | 16.3 | 11.5 | 6.3 | 4.5 | 4.2 | 3.7 |
| Earnings from Continuing Operations | ||||||||||||||||
| Interest Expense | 5.2 | 5.2 | 0.2 | 0.0 | 0.0 | 2.2 | 1.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Interest & Investment Income | 13.9 | 13.1 | 4.9 | 3.1 | 1.0 | 0.2 | 0.2 | 0.7 | 0.6 | 0.2 | 0.1 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 |
| Net Interest Expenses | — | — | — | (3.1) | (1.0) | 2.0 | 1.1 | (0.7) | (0.6) | (0.2) | (0.1) | (0.0) | 0.0 | 0.0 | (0.1) | (0.0) |
| Asset Writedown | — | — | — | — | — | — | — | — | — | — | 0.2 | 0.2 | 0.2 | 0.1 | 0.1 | 0.1 |
| EBT, Incl. Unusual Items | 84.7 | 75.2 | 56.9 | 39.5 | 27.5 | 34.3 | 27.4 | 21.7 | 28.4 | 21.1 | 16.2 | 11.4 | 6.3 | 4.3 | 4.0 | 3.8 |
| Income Tax Expense | 19.1 | 17.5 | 12.8 | 9.4 | 6.9 | 7.4 | 6.1 | 3.7 | 5.5 | 3.9 | 5.7 | 3.7 | 2.4 | 1.1 | 1.4 | 1.6 |
| Net Income | ||||||||||||||||
| Net Income | 65.6 | 57.7 | 44.0 | 30.1 | 20.6 | 26.9 | 21.2 | 17.9 | 22.9 | 17.2 | 10.6 | 7.8 | 3.9 | 3.2 | 2.6 | 2.1 |
| Per Share | ||||||||||||||||
| Basic EPS | 2.87 | 2.55 | 1.96 | 1.36 | 0.94 | 1.27 | 1.05 | 0.91 | 1.18 | 0.91 | 0.57 | 0.44 | 0.24 | 0.21 | 0.17 | 0.14 |
| Diluted EPS | 2.68 | 2.52 | 1.93 | 1.34 | 0.93 | 1.25 | 1.04 | 0.88 | 1.13 | 0.86 | 0.55 | 0.42 | 0.23 | 0.20 | 0.16 | 0.13 |
| Dividend per Share | — | 0.80 | 0.64 | 0.56 | 0.50 | 0.44 | 0.38 | 0.34 | 0.28 | 0.22 | 0.18 | 0.16 | 0.14 | 0.12 | 0.10 | 0.08 |
| Basic Weighted Avg Shares | 22.9 | 22.6 | 22.5 | 22.2 | 22.0 | 21.2 | 20.2 | 19.8 | 19.4 | 19.0 | 18.5 | 17.8 | 16.6 | 15.3 | 15.2 | 15.5 |
| Diluted Weighted Avg Shares | 24.5 | 22.9 | 22.8 | 22.4 | 22.2 | 21.5 | 20.5 | 20.3 | 20.2 | 20.0 | 19.2 | 18.3 | 17.0 | 15.8 | 15.6 | 16.0 |
| Supplemental | ||||||||||||||||
| EBITDA | — | 78.3 | 61.9 | 46.2 | 36.3 | 47.5 | 37.2 | 26.6 | 32.5 | 25.2 | 19.9 | 14.9 | 9.7 | 7.3 | 6.5 | 5.7 |
| EBIT | 77.3 | 67.9 | 52.3 | 36.7 | 26.8 | 36.4 | 28.8 | 21.2 | 28.2 | 21.1 | 16.3 | 11.5 | 6.3 | 4.5 | 4.2 | 3.7 |
| Effective Tax Rate | 22.5% | — | — | 23.7% | 24.9% | 21.5% | 22.4% | 17.3% | 19.3% | 18.6% | 34.8% | 32.1% | 38.1% | 26.0% | 35.6% | 42.9% |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.